A finding of “no hemodynamically significant stenosis” means that none of the narrowings in your coronary arteries are severe enough to measurably restrict blood flow to the heart muscle. In most clinical contexts, this is reassuring news and rules out the need for procedures like stenting or bypass surgery. But the phrase is more nuanced than a clean bill of health, and understanding what it does and does not tell you about your heart matters for what comes next.
What the Phrase Actually Means
Doctors assess whether a coronary artery narrowing is “hemodynamically significant” by measuring whether it reduces blood flow enough to starve the heart muscle during exertion. The standard tool for this is called fractional flow reserve, or FFR. A pressure sensor is threaded through the artery while a drug forces the heart to work harder, and the resulting pressure ratio tells the cardiologist how much flow the narrowing is blocking. An FFR value above 0.80 is classified as not hemodynamically significant, meaning the artery can still deliver enough blood even under stress.1PubMed Central. Hemodynamic impact of coronary stenosis using computed tomography: comparison between noninvasive fractional flow reserve and 3D fusion of coronary angiography with stress myocardial perfusion The same threshold is used in noninvasive versions of the test that estimate FFR from CT scans.2PubMed. Non-invasive prediction of hemodynamically significant coronary artery stenoses by contrast density difference in coronary CT angiography
So when your report says “no hemodynamically significant stenosis,” it is telling you that any plaque or narrowing the scan found is not severe enough to choke off blood supply through that particular measurement. That is genuinely good news in one important way: it means you almost certainly do not need a stent or bypass right now, and the immediate risk of a flow-limiting blockage causing a heart attack is low compared to someone with obstructive disease.
Why It Is Not the Same as “No Heart Disease”
Here is where many people, and some doctors, get tripped up. A narrowing can be too mild to restrict flow and still contain plaque that poses a risk. A large study of veterans who had coronary angiography found that even nonobstructive disease carries a measurably higher risk of heart attack compared with completely clean arteries. Among patients with nonobstructive plaque in two vessels, the one-year heart attack rate was roughly five times higher than in those with no visible plaque at all, and in those with nonobstructive disease in all three major arteries, the hazard ratio for heart attack was about 4.5 compared to patients with no apparent disease.3PubMed Central. Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction Those are small absolute numbers, but they establish a clear dose-response: more plaque, even when none of it is flow-limiting, means more risk.
A separate study using CT angiography in over 2,500 symptomatic patients found that the mere presence of any nonobstructive plaque roughly doubled the risk of death during follow-up, after adjusting for traditional risk factors. Patients with nonobstructive disease spread across five or more coronary segments had a fivefold higher mortality risk than those with clean arteries.4PubMed. Mortality risk in symptomatic patients with nonobstructive coronary artery disease The reassuring flip side: patients without any visible plaque had a very low death rate of about 0.34% per year.
The practical takeaway is that “no hemodynamically significant stenosis” sits on a spectrum. If your arteries are genuinely clean with no plaque at all, that is excellent. If you have scattered mild plaque that does not restrict flow, you are in a much better position than someone with severe blockages, but you are not in the same category as someone with pristine arteries.
How Nonobstructive Plaque Can Still Cause a Heart Attack
One of the most counterintuitive facts in cardiology is that many heart attacks originate from plaques that were not severe enough to limit blood flow before they ruptured. The mechanism is straightforward: a plaque does not have to be large to be unstable. If the fibrous cap covering a fatty deposit is thin or inflamed, it can crack open. When it does, the body treats the exposed material as a wound and sends clotting factors to the site, which can form a blood clot large enough to suddenly block the artery. This process can happen in arteries that looked only mildly narrowed on a prior angiogram.5PubMed Central. Myocardial infarction with non-obstructive coronary arteries: what is the prognosis?
When patients have a confirmed heart attack but their angiogram shows no significant blockages, cardiologists call it MINOCA, short for myocardial infarction with non-obstructive coronary arteries. Advanced imaging with optical coherence tomography has revealed that plaque disruption and clot formation are not uncommon in these cases.6PubMed. Mechanisms of Myocardial Infarction in Patients With Nonobstructive Coronary Artery Disease: Results From the Optical Coherence Tomography Study MINOCA has multiple possible causes beyond plaque rupture, including coronary artery spasm, spontaneous dissection of a coronary artery wall, and tiny blood clots that travel from elsewhere. It is not a benign diagnosis; it requires a thorough workup to identify the specific cause, because treatment depends on which mechanism was responsible.7PubMed Central. MINOCA: Myocardial infarction no obstructive coronary artery disease
When Chest Pain Persists Despite Open Arteries
Roughly half of all patients who undergo coronary angiography for chest pain turn out to have no significant blockages.8PubMed Central. Pathophysiology and Diagnosis of Coronary Functional Abnormalities For many of these people, the pain is real and cardiac in origin. The condition now has a formal name: INOCA, or ischemia with non-obstructive coronary arteries. The underlying problem usually involves either spasm of the larger coronary arteries or dysfunction of the tiny blood vessels (the microvasculature) that ultimately deliver oxygen to the heart muscle.9PubMed Central. INOCA/ANOCA: Mechanisms and novel treatments
Coronary vasospasm, sometimes called Prinzmetal’s or variant angina, is a temporary but intense constriction of a coronary artery that can slash blood flow dramatically even in a vessel with no fixed narrowing.10PubMed. Prinzmetal’s angina It tends to be underdiagnosed because the spasm may not be happening during a routine angiogram.11PubMed Central. Coronary vasospasm: A narrative review Coronary microvascular dysfunction is the other major player. Here, the problem is not in the large arteries that show up on an angiogram but in the microscopic vessels downstream. These vessels fail to dilate properly under stress, leaving patches of heart muscle oxygen-starved even though the big pipes look fine.12PubMed Central. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade
If you have been told your arteries are open but you are still having chest pain, tightness, or shortness of breath with exertion, these conditions are worth investigating. They are treatable once identified, but they require specific testing that goes beyond a standard angiogram.
The Disproportionate Impact on Women
Nonobstructive coronary disease and its functional cousins hit women harder and more often. Coronary microvascular dysfunction has been detected in up to half of women presenting with chest pain symptoms, and it has a clear female preponderance.13PubMed Central. Coronary microvascular dysfunction in women: an overview of diagnostic strategies A study of nearly 1,400 patients with stable chest pain and nonobstructive arteries found that women were more than four times as likely as men to have microvascular dysfunction and more than twice as likely to have epicardial vasospasm when tested with a provocative agent.14Cardiovascular Research. Sex differences in non-obstructive coronary artery disease
Historically, women whose angiograms came back clean were often told nothing was wrong, sometimes with the implication that the pain was psychosomatic. That framing has shifted considerably, with emerging evidence showing that more extensive nonobstructive disease in women carries risks similar to obstructive disease in some populations.15Journal of the American College of Cardiology. Emergence of Nonobstructive Coronary Artery Disease: A Woman’s Problem and Need for Change in Definition on Angiography The economic toll is also substantial. A study from the NIH-sponsored Women’s Ischemia Syndrome Evaluation found that about 20% of women with nonobstructive disease were hospitalized for chest pain within five years, and the volume of repeat catheterizations and angina-related hospital visits was actually higher for women with nonobstructive disease than for those with single-vessel obstructive disease in the first year of follow-up.16PubMed. The economic burden of angina in women with suspected ischemic heart disease
What Treatment Looks Like When Arteries Are Not Blocked
The absence of a significant blockage does not mean there is nothing to do. If nonobstructive plaque is present, reducing its progression and stabilizing it are the primary goals. Intensive statin therapy has been shown across clinical trials to safely reduce overall plaque burden and favorably change plaque composition when LDL cholesterol is driven to very low levels.17Nature Reviews Cardiology. Atherosclerotic plaque stabilization and regression: a review of clinical evidence Data from the CONFIRM registry, which tracked patients with nonobstructive coronary disease for five years, found that statin use was independently associated with a roughly 40% lower rate of major adverse cardiovascular events.18PubMed Central. Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry
Aspirin’s role is less clear-cut. That same CONFIRM analysis found no significant reduction in heart attacks or overall adverse events with aspirin in the nonobstructive group. A separate cohort study found that aspirin was associated with lower death rates only among higher-risk patients with nonobstructive disease, not across the board.19PLOS ONE. Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study For patients who have already had a MINOCA event, a meta-analysis of dual antiplatelet therapy found it was associated with a reduction in all-cause death but showed no significant benefit for preventing further heart attacks or major cardiovascular events overall.20PubMed Central. Effect of dual antiplatelet therapy on prognosis of patients with myocardial infarction with nonobstructive coronary artery disease A meta-analysis The evidence, in other words, is still catching up with the complexity of the condition.
Lifestyle intervention is also part of the picture. A randomized trial found that an intensive dietary intervention produced a meaningful reduction in vulnerable (noncalcified) plaque components compared with standard care in patients with nonobstructive disease, even though total plaque volume did not change significantly in either group.21PubMed. High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonobstructive Coronary Disease: A Randomized Study The shift from dangerous soft plaque toward more stable calcified plaque may matter more than the overall plaque volume.
The Diagnostic Gap and Why It Matters
A persistent problem with nonobstructive coronary disease is that the diagnosis itself can lead to under-treatment. When patients with MINOCA leave the hospital, they are less likely to be prescribed secondary preventive medications, less likely to receive structured follow-up, and less likely to hit treatment targets compared with patients whose heart attacks involved obvious blockages.22PLOS ONE. Adherence to secondary preventive treatment following myocardial infarction with and without obstructive coronary artery disease Part of this is doctor-side: if the angiogram looks relatively clean, the urgency to prescribe aggressive therapy drops. Part is patient-side: when you are told your arteries are not blocked, it is natural to feel like the problem has been ruled out, which makes it harder to stay motivated about medications.
Specialized testing can close this gap. In patients with angina and open arteries, coronary reactivity testing, which directly evaluates how the small and large coronary vessels respond to pharmacological challenge, was associated with substantially lower healthcare costs over follow-up compared with patients who had standard angiography alone. The total cost difference was dramatic: roughly $14,000 versus nearly $38,000 per patient, largely driven by reduced repeat imaging, procedures, and testing in those who received the more targeted diagnostic workup.23PubMed. Coronary Reactivity Assessment Is Associated With Lower Health Care-Associated Costs in Patients Presenting With Angina and Nonobstructive Coronary Artery Disease Getting the right diagnosis early saves money and, more importantly, spares patients the cycle of repeated inconclusive tests.
How AI Is Changing What “Nonobstructive” Means
Traditional imaging tells you the size of a narrowing and whether it restricts flow. It tells you much less about what the plaque is made of or how likely it is to rupture. That is changing. Artificial intelligence tools can now analyze CT scans to characterize plaque composition in detail, distinguishing between dense calcified deposits (generally stable) and soft, fatty, low-attenuation deposits (more dangerous). In one study, an AI-enabled plaque analysis found that necrotic core volume was the strongest predictor of a future heart attack among patients whose blockages were not initially flow-limiting, carrying a sevenfold higher risk than total plaque volume alone.24PubMed Central. The association of artificial intelligence-enabled coronary plaque analysis with future non-ST elevation myocardial infarction
Another AI model combining plaque features with hemodynamic data showed stronger predictive power for acute coronary syndrome than traditional risk models, with an area under the curve of 0.84 in a validation cohort.25PubMed. Artificial Intelligence-Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome In women specifically, an AI-derived score incorporating high-risk plaque features was independently associated with the severity of angina symptoms, even when the narrowings would traditionally be dismissed as mild.26Communications Medicine. Artificial intelligence-enabled plaque characterization from coronary computed tomography establishes basis of angina in women with nonobstructive atherosclerosis These tools are not yet standard in every cardiology practice, but they represent a shift toward evaluating plaque quality rather than just plaque quantity.
Anti-Inflammatory Approaches on the Horizon
Inflammation plays a central role in making plaques unstable, regardless of their size. Randomized studies have demonstrated that therapies specifically targeting inflammatory pathways can reduce the risk of cardiovascular events, though these treatments have not yet been widely adopted in everyday practice.27PubMed Central. Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes For patients with nonobstructive disease, this line of research is particularly relevant. If the danger lies not in the degree of narrowing but in the biological activity of the plaque, then calming that activity could be more protective than trying to open up a vessel that is not meaningfully blocked.
Some of these approaches use drugs originally developed for autoimmune conditions, repurposed to tamp down the specific inflammatory molecules that destabilize coronary plaques. Others aim at residual inflammatory risk, the elevated inflammation that persists even after cholesterol has been well controlled with statins. The field is still working out which patients benefit most and whether the infection and immune-suppression trade-offs are worth it in lower-risk populations. But the direction is clear: the future of managing nonobstructive coronary disease will increasingly focus on what the plaque is doing, not just how much of the artery it fills.